**Arecor Therapeutics plc 2025 Business Update Summary**
**Key Highlights**
**Focus Areas** Continued emphasis on diabetes and oral peptide delivery, targeting multi-billion-dollar markets.
**Partnerships**
Signed a co-development deal with Sequel Med Tech in September 2025 to combine Arecor’s ultra-concentrated, ultra-rapid-acting insulin (AT278) with Sequel’s twiist™ Automated Insulin Delivery (AID) system.
Secured a $11 million non-dilutive royalty financing agreement with Ligand Pharmaceuticals, with $7 million received upfront.
**AT278 Progress**
Positive Type C meeting with the FDA in September 2025 on a Phase 2 clinical study design for AT278 in combination with AID systems for type 1 and type 2 diabetes patients.
Collaboration with Sequel to fund development for the Phase 2 trial, with discussions ongoing for broader commercialization.
**Oral Peptide Delivery**
R&D focused on improving oral bioavailability of peptides, starting with GLP-1 (semaglutide).
Non-clinical pharmacokinetic studies underway, with a patent application filed in Q4 2025 for novel compositions to enhance oral peptide bioavailability.
**Financials**
Total revenue of £3.1 million (2024£5.1 million), with the decrease attributed to the cessation of operations at Tetris Pharma.
Cash and cash equivalents increased to £6.1 million (2024: £3.2 million), exceeding expectations due to favorable performance at Tetris.
**CEO Commentary (Dr. Sarah Howell)**
Highlighted strategic focus on AT278 and oral peptide delivery, leveraging Arecor’s technology edge in high-growth markets. Emphasized the potential of AT278 combined with Sequel’s AID system to address unmet needs in diabetes care, supported by a strong financial position.
**About Arecor**
A clinical-stage biopharmaceutical company based in Cambridge, UK, focused on diabetes and cardiometabolic diseases. Lead product AT278 is an ultra-concentrated, ultra-rapid-acting insulin, with additional focus on oral peptide delivery platforms. Listed on AIM (AIM: AREC).
**Conclusion**
Arecor made significant progress in 2025, advancing AT278 through regulatory and partnership milestones, while also progressing its oral peptide delivery platform. Financial stability and strategic collaborations position the company for growth in diabetes and cardiometabolic markets.